Supplemental material for Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK by Gordon Mazibrada, Charlotte Sharples and Ines Perfect in Multiple Sclerosis Journal – Experimental, Translational and Clinical</p
Jong-Mi Lee,1 May H Han1,2 1Stanford Healthcare, Multiple Sclerosis Center, 2Department of Neurolog...
Online ahead of printInternational audienceIntroduction: It is important to confirm the effectivenes...
Supplemental material, MSJ795332_supplementary_table_2 for Effects and mechanisms of differently cue...
<p>Supplementary Material, Supplementary_files_final_version_PREFERMS for Phase IV study of retentio...
Clemens Warnke1,2, Olaf St&uuml;ve3,4, Hans-Peter Hartung1, Anna Fogdell-Hahn2, Bernd C Kieseier...
Editors ’ Note: Oral medications for multiple sclerosis (MS), such as fingolimod, are an attractive ...
Fingolimod, the first oral immunomodulatory treat-ment for relapsing multiple sclerosis (MS), acts b...
Supplemental material, MSJ803769_supplementary_material for Inclusion criteria used in trials of peo...
<p>Supplemental material, MSJ790390_supplementary_material for Determinants of therapy switch in mul...
Fingolimod is a multiple sclerosis treatment licensed in Europe since 2011. Its efficacy has been de...
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -...
Fingolimod, the first oral disease-modifying therapy (DMT) approved for the treatment of multiple sc...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189678 for Enhancing involvement of people w...
Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstr...
To directly compare fingolimod (FNG) and dimethyl fumarate (DMF) on no evident disease activity (NED...
Jong-Mi Lee,1 May H Han1,2 1Stanford Healthcare, Multiple Sclerosis Center, 2Department of Neurolog...
Online ahead of printInternational audienceIntroduction: It is important to confirm the effectivenes...
Supplemental material, MSJ795332_supplementary_table_2 for Effects and mechanisms of differently cue...
<p>Supplementary Material, Supplementary_files_final_version_PREFERMS for Phase IV study of retentio...
Clemens Warnke1,2, Olaf St&uuml;ve3,4, Hans-Peter Hartung1, Anna Fogdell-Hahn2, Bernd C Kieseier...
Editors ’ Note: Oral medications for multiple sclerosis (MS), such as fingolimod, are an attractive ...
Fingolimod, the first oral immunomodulatory treat-ment for relapsing multiple sclerosis (MS), acts b...
Supplemental material, MSJ803769_supplementary_material for Inclusion criteria used in trials of peo...
<p>Supplemental material, MSJ790390_supplementary_material for Determinants of therapy switch in mul...
Fingolimod is a multiple sclerosis treatment licensed in Europe since 2011. Its efficacy has been de...
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -...
Fingolimod, the first oral disease-modifying therapy (DMT) approved for the treatment of multiple sc...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189678 for Enhancing involvement of people w...
Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstr...
To directly compare fingolimod (FNG) and dimethyl fumarate (DMF) on no evident disease activity (NED...
Jong-Mi Lee,1 May H Han1,2 1Stanford Healthcare, Multiple Sclerosis Center, 2Department of Neurolog...
Online ahead of printInternational audienceIntroduction: It is important to confirm the effectivenes...
Supplemental material, MSJ795332_supplementary_table_2 for Effects and mechanisms of differently cue...